92903-30-5

Upstream product

• 107841-28-1 trans 2-(p-methoxyphenyl)-3-methyl-5-morpholinone 
• 107841-22-5 p-methoxy-(N,N-dibenzylamino)-propiophenone 
• 107841-28-1 cis 2-(p-methoxyphenyl)-3-methyl-5-morpholinone 
• 63991-23-1 erythro 1-(p-methoxyphenyl)-2-amino-1-propanol hydrochloride 
• 107841-27-0 2-Bromo-N-[2-hydroxy-2-(4-methoxy-phenyl)-1-methyl-ethyl]-acetamide 
• 21086-33-9 2-bromo-1-(4-methoxyphenyl)-1-propanone 
• 63991-23-1 threo 1-(p-methoxyphenyl)-2-amino-1-propanol hydrochloride 
• 107841-27-0 2-Bromo-N-[2-hydroxy-2-(4-methoxy-phenyl)-1-methyl-ethyl]-acetamide 

Relevant academic research and scientific papers

PHENYLMORPHOLINES AND ANALOGUES THEREOF

Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression.

SYNTHESIS OF RIGID DOPAMINE CONGENERS: CIS AND TRANS 2-(p-METHOXYPHENYL)-3-METHYLMORPHOLINE

A synthetic pathway is reported for the preparation of cis and trans forms of 2-(p-methoxyphenyl)-3-methyl-morpholine from the same key-compound, the p-methoxy- -(N,N'-dibenzylamino)-propiophenone, through stereospecific reduction processes.